PR

Pierrel SpAMIL Pierrel Stock Report

Last reporting period 30 Jun, 2023

Updated —

Last price

Market cap $B

0.015

Micro

Exchange

XMIL - Borsa Italiana S.P.A.

PRL.MI Stock Analysis

PR

Uncovered

Pierrel SpA is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

53/100

Moderate score

Market cap $B

0.015

Dividend yield

Shares outstanding

228.88 B

Pierrel SpA engages in the development, manufacturing, and marketing of medical therapies for the pharmaceutical, bio-pharmaceutical, and life science industries. The company is headquartered in Capua, Caserta and currently employs 105 full-time employees. The company went IPO on 2006-05-23. The firm specializes in the pharmaceutical research, development and the manufacture of medicines. The company operates through three segments. The Contract Manufacturing segment covers research and development of various types of drugs, such as Tube vials, bottles, ampoules, drops, sprays, tablets and gels. The company manufactures the drugs in the production facility in Capua, which consists of warehouses, chemical and microbiological laboratories, offices and utilities buildings. The Pharma segment is active in the development, registration and licensing of new drugs and medical devices. The Tech-driven Contract Research & Development Organization segment provides research of existing drugs for the treatment of rare diseases, among others.

View Section: Eyestock Rating